Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Curie

Université Pierre Et Marie Curie (paris Vi)

Philipe Maillard

David Grierson

Ludger Johannes

Sylvie Robine

Jean-Claude Florent

Jacky Roger

The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gbreceptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein

[object Object]

Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

The invention relates to new compounds for cancer therapy or diagnosis and to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein-STxB is the Shiga Toxin B subunit or a functional equivalent thereof, -Z(n) wherein n is 0 or 1, Z is an amino-acid residue devoid of sulfydryl groups, or is a polypeptide, -T is a molecule linked by a covalent bound to the S part of Cys, selected from: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, - Y(m) wherein m is 0 or 1, Y is a linker between T and Cys, which is either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into cells.

Growing community of inventors

Saint-Cyr-l'Ecole, France

Philipe Maillard